Help
RSS
API
Feed
Maltego
Contact
Domain > www.veltassa.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2025-03-18
54.197.52.52
(
ClassC
)
2025-03-18
54.224.17.253
(
ClassC
)
2026-02-13
52.200.140.178
(
ClassC
)
Port 80
HTTP/1.1 200 OKDate: Fri, 13 Feb 2026 23:35:13 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveServer: Cache-Control: must-revalidate, no-cache, privateContent-language: enX-Content-Type-Options: nosniffX-Frame-Options: SAMEORIGINExpires: Sun, 19 Nov 1978 05:00:00 GMTX-Dynamic-Cache: MISSX-Cache: HIT !DOCTYPE html>html langen dirltr prefixcontent: http://purl.org/rss/1.0/modules/content/ dc: http://purl.org/dc/terms/ foaf: http://xmlns.com/foaf/0.1/ og: http://ogp.me/ns# rdfs: http://www.w3.org/2000/01/rdf-schema# schema: http://schema.org/ sioc: http://rdfs.org/sioc/ns# sioct: http://rdfs.org/sioc/types# skos: http://www.w3.org/2004/02/skos/core# xsd: http://www.w3.org/2001/XMLSchema# > head> !-- Google Tag Manager --> script>(function(w,d,s,l,i){wlwl||;wl.push({gtm.start: new Date().getTime(),event:gtm.js});var fd.getElementsByTagName(s)0, jd.createElement(s),dll!dataLayer?&l+l:;j.asynctrue;j.src https://www.googletagmanager.com/gtm.js?id+i+dl;f.parentNode.insertBefore(j,f); })(window,document,script,dataLayer,GTM-MSRZ698);/script> !-- End Google Tag Manager --> meta charsetutf-8 />meta namedescription contentVeltassa® is a reliable and easy to use hyperkalaemia treatment with no sodium-associated risk. />meta namerobots contentindex />link relshortlink hrefhttps://www.veltassa.com/ />link relcanonical hrefhttps://www.veltassa.com/ />meta propertyog:site_name contentVeltassa Global />meta propertyog:url contenthttps://www.veltassa.com/global />meta propertyog:title contentVeltassa Global | Home />meta propertyog:description contentVeltassa® is a reliable and easy to use hyperkalaemia treatment with no sodium-associated risk. />meta nameMobileOptimized contentwidth />meta nameHandheldFriendly contenttrue />meta nameviewport contentwidthdevice-width, initial-scale1.0 />script srchttps://cdn.cookielaw.org/scripttemplates/otSDKStub.js data-document-languagetrue typetext/javascript charsetUTF-8 data-domain-scriptbf1aaf89-6c64-444d-914f-e15ac0a2c72d>/script>script typetext/javascript> function OptanonWrapper() { }/script>link relicon href/themes/custom/veltassa_global/favicon.ico typeimage/vnd.microsoft.icon />link relalternate hreflangen hrefhttps://www.veltassa.com/ />link relalternate hreflangch-de hrefhttps://www.veltassa.com/ch-de />link relalternate hreflangch-fr hrefhttps://www.veltassa.com/ch-fr />/head-placeholder> title>Veltassa Global | Home/title> link relstylesheet mediaall href/sites/multisite/veltassa/files/css/css_skRohsATvY4NnKMFuYiPrAFL-zg2zfuaKrfyt-vUaH0.css?delta0&languageen&themeveltassa_global&includeeJwrriwuSc3VT0osTtUpS80pSSwuToxPz8lPSszRh1C6ycXFACYjDuU />link relstylesheet mediaall href/sites/multisite/veltassa/files/css/css_vyrW_mFVdeVaCXgoqIXoLpODuPkKY8GCxzVkpSi6JC0.css?delta1&languageen&themeveltassa_global&includeeJwrriwuSc3VT0osTtUpS80pSSwuToxPz8lPSszRh1C6ycXFACYjDuU />/css-placeholder> /js-placeholder> /head> body classglobal language_en class> !-- Google Tag Manager (noscript) --> noscript> iframe srchttps://www.googletagmanager.com/ns.html?idGTM-MSRZ698 height0 width0 styledisplay:none;visibility:hidden>/iframe> /noscript> !-- End Google Tag Manager (noscript) --> div classdialog-off-canvas-main-canvas data-off-canvas-main-canvas> div> div idlogin-popup> div idlogin-popup-modal-1 classpopup-modal> div classtitle-row> h4>Help us guide you to the right place/h4> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div classus-row> h5>I reside in the United States/h5> a href/patient/>Visit the US siteimg src/themes/custom/veltassa_global/images/dark_arrow.png>/a> /div> hr> div classrow>I do not reside in the United States/div> div classbig-buttons-row> div idiam-hcp-button classlinkto big-button data-hcptrue data-linktologin-popup-modal-2> i data-hcptrue classfal fa-stethoscope>/i> h4 data-hcptrue>I am a health/h4> h4 data-hcptrue>care professional/h4> p data-hcptrue>This is me, continueimg src/themes/custom/veltassa_global/images/dark_arrow.png>/p> /div> div idiam-not-hcp-button data-hcpfalse classlinkto big-button data-linktologin-popup-modal-3> i data-hcpfalse classfal fa-user>/i> h4 data-hcpfalse>I am span>not/span> a health/h4> h4 data-hcpfalse>care professional/h4> p data-hcpfalse>This is me, continueimg src/themes/custom/veltassa_global/images/dark_arrow.png>/p> /div> /div> /div> div idlogin-popup-modal-2 classpopup-modal> div classtitle-row> h4>Help us guide you to the right place/h4> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div idconfirm-big-button classbig-buttons-row> div idiam-hcp-button classbig-button> i classfal fa-stethoscope>/i> h4>I am a health/h4> h4>care professional/h4> /div> /div> div classcountries-row> div classcheckbox data-checkednone> i classfar fa-check>/i> /div> p>I am practicing from:/p> div classcountry-selector> div classcurrent-country> img src/themes/custom/veltassa_global/images/countries/austria.png altAustrian flag/> p>Austria/p> i classfar fa-chevron-down>/i> /div> ul classdefault-country-selector> li classselected-country data-valueaustria data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/austria-min.png altAustrian flag/> p>Austria/p> /li> li data-valuebelgium data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/belgium-min.png altBelgium flag/> p>Belgium/p> /li> li data-valuegermany data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/germany-min.png altGermany flag/> p>Germany/p> /li> li data-valueireland data-validatornone> img src/themes/custom/veltassa_global/images/countries/ireland-min.png altIreland flag/> p>Ireland/p> /li> li data-valueitaly data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/italy-min.png altItaly flag/> p>Italy/p> /li> li data-valuenetherlands data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/netherlands-min.png altNetherlands flag/> p>Netherlands/p> /li> li data-valueportugal data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/portugal-min.png altPortugal flag/> p>Portugal/p> /li> li data-valuespain data-validatornone> img src/themes/custom/veltassa_global/images/countries/spain-min.png altSpain flag/> p>Spain/p> /li> li data-valueswitzerland data-validatorswissrx-modal data-swissyes> img src/themes/custom/veltassa_global/images/countries/switzerland-min.png altSwitzerland flag/> p>Switzerland/p> /li> li data-valueother data-validatornotavailable-modal> p>Other/p> /li> /ul> /div> /div> hr> div classbuttons-row> div classbtn linkto back-button data-linktologin-popup-modal-1>Back to options/div> div classbtn linkto locked-button data-linktocustom>Continue/div> div classcontinue-button-cover>/div> /div> /div> div idlogin-popup-modal-3 classpopup-modal> div classtitle-row> h4>Help us guide you to the right place/h4> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div idconfirm-big-button classbig-buttons-row> div idiam-not-hcp-button classbig-button> i classfal fa-user>/i> h4>I am span>not/span> a health/h4> h4>care professional/h4> /div> /div> div classcountries-row> div classcheckbox data-checkednone> i classfar fa-check>/i> /div> p>I am residing in:/p> div classcountry-selector> div classcurrent-country> img src/themes/custom/veltassa_global/images/countries/austria.png altAustrian flag/> p>Austria/p> i classfar fa-chevron-down>/i> /div> ul classdefault-country-selector> li classselected-country data-valueaustria> img src/themes/custom/veltassa_global/images/countries/austria-min.png altAustrian flag/> p>Austria/p> /li> li data-valuebelgium> img src/themes/custom/veltassa_global/images/countries/belgium-min.png altBelgium flag/> p>Belgium/p> /li> li data-valuegermany> img src/themes/custom/veltassa_global/images/countries/germany-min.png altGermany flag/> p>Germany/p> /li> li data-valueireland> img src/themes/custom/veltassa_global/images/countries/ireland-min.png altIreland flag/> p>Ireland/p> /li> li data-valueitaly> img src/themes/custom/veltassa_global/images/countries/italy-min.png altItaly flag/> p>Italy/p> /li> li data-valuenetherlands> img src/themes/custom/veltassa_global/images/countries/netherlands-min.png altNetherlands flag/> p>Netherlands/p> /li> li data-valueportugal> img src/themes/custom/veltassa_global/images/countries/portugal-min.png altPortugal flag/> p>Portugal/p> /li> li data-valuespain> img src/themes/custom/veltassa_global/images/countries/spain-min.png altSpain flag/> p>Spain/p> /li> li data-valueswitzerland> img src/themes/custom/veltassa_global/images/countries/switzerland-min.png altSwitzerland flag/> p>Switzerland/p> /li> li data-valueother> p>Other/p> /li> /ul> /div> /div> hr> div classbuttons-row> div classbtn linkto back-button data-linktologin-popup-modal-1>Back to options/div> a classbtn locked-button hrefhttps://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor#main-content-area>Continue/a> div classcontinue-button-cover>/div> /div> /div> div iddoccheck-modal classpopup-modal> div classtitle-row> div classback-button-on-top linkto data-linktologin-popup-modal-2> i classfas fa-chevron-left>/i> h4 data-i18nbackTo>Zurück zu den Optionen/h4> /div> i classfal fa-times> div classclose-popup data-i18nchoseOption>Bitte wählen Sie eine der folgenden Optionen!/div> /i> /div> form actionhttps://login.doccheck.com/ methodpost target_top> input typehidden namelogin_id value2000000016781> input typehidden namedc_iframe_referer valuehttps://veltassa.com/activated> input typehidden namestrDcLanguage valuede data-i18nlangCode> input typehidden nameintDcLanguageId value148> input typehidden nameintLoginVersion value3> input typehidden namestrDesignVersion valuelogin_xl> input typehidden nameintLogoutSwitch value0> div classintro-part> img src/themes/custom/veltassa_global/images/doccheck-logо.png altDoc Check Logo /> p data-i18nintro>Wenn Sie Mitglied der Community der medizinischen Fachkräfte sind, melden Sie sich bitte an./p> /div> div classinput-part> input typetext nameusername iddc_username autocapitalizeoff autocorrectoff placeholderBenutzername autocompleteoff data-i18nusername /> input typepassword namepassword iddc_password autocapitalizeoff autocorrectoff placeholderPassword eingeben autocompleteoff data-i18npassword/> div iddoc-check-login onclickdocument.querySelector(#doccheck-modal form).submit(); data-i18nlogin>Einloggen/div> /div> div classdoccheck-links> a hrefhttps://www.doccheck.com/de/account/register/ data-i18naccess>Registrierung/a> a hrefhttps://www.doccheck.com/de/account/password/reminder/ data-i18npasswordForgotten>Passwort vergessen?/a> /div> /form> /div> div idswissrx-modal classpopup-modal> div classtitle-row> div classback-button-on-top linkto data-linktologin-popup-modal-2> i classfas fa-chevron-left>/i> h4>Back to options/h4> /div> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div classintro-part> img src/themes/custom/veltassa_global/images/swissrx-logo.png altSwiss Rx logo /> p>Bitte verwenden Sie als Benutzernamen die E-Mail Adresse, welche Sie bei der Registration angegeben hatten. Falls Sie das Passwort vergessen haben, können Sie sich einen Reaktivierungslink zustellen lassen. Alternativ ist für bereits registrierte Health Professionals auch eine Anmeldung mit der HPC-Card von FMH oder pharmaSuisse möglich./p> /div> div classinput-part> form nameformPost actionhttps://swiss-rx-login.ch/ methodpost> input typehidden nameGLN idGLN value7601001001862/> input typehidden nameBackURL idBackURL valuehttps://www.veltassa.com/login/validated/> input typehidden nameShowText idShowText valueViforPharm/> input typehidden nameLang idLang valueDE/> input typesubmit valueLog in> /form> div classswissrx-links> a hrefhttps://swiss-rx-login.ch/Account/LogOn>Passwort Vergessen/a> /div> /div> /div> div idnotavailable-modal classpopup-modal> div classtitle-row> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div classmodal-title-text>Veltassa is not available in your country,br>please proceed./div> hr> div classbuttons-row> div classbtn linkto back-button data-linktologin-popup-modal-1>Back to options/div> a classbtn continue-button hrefhttps://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor#main-content-area>Continue/a> /div> /div>/div> /div> div idheader> div classinner-header> a classheader-logo href/global data-event-actionClick data-event-categoryHeader data-event-labelHeader logo> img loadinglazy src/sites/multisite/veltassa/files/2024-02/veltassa_logo_new_3.png width372 height208 altVeltassa logo typeoffoaf:Image /> /a> div classtop-menu> div classbutton> a hrefhttps://www.ema.europa.eu/en/medicines/human/EPAR/veltassa>Prescribing Information/a>/div> div classbutton report-pop-button> Adverse Event Reportingi classfal fa-plus-square header-top-menu-element>/i>/div>/div>div classline>/div>div classsearch-menu-item> Searchi classfar fa-search search-icon>/i>/div>div classmobile-menu-btn> div classmenu-line long-menu-line>/div> div classmenu-line short-menu-line>/div>/div>nav rolenavigation aria-labelledbyblock-mainnavigation-menu idblock-mainnavigation> h2 classvisually-hidden idblock-mainnavigation-menu>Main navigation/h2> ul> li> a href/global/what-is-hyperkalaemia data-drupal-link-system-pathnode/351>What is Hyperkalaemia?/a> /li> li> a href/global/hk-challenge-in-ckd data-drupal-link-system-pathnode/331>HK Challenge in CKD/a> /li> li> a href/global/hk-challenge-in-hf data-drupal-link-system-pathnode/336>HK Challenge in HF/a> /li> li> a href/global/about data-drupal-link-system-pathnode/291>About Veltassa/a> /li> li> a href/global/clinical-experience data-drupal-link-system-pathnode/296>Clinical Experience/a> /li> li> a href/global/resources data-drupal-link-system-pathnode/346>Resources/a> /li> /ul> /nav>div idblock-searchform> form action/search methodget idviews-exposed-form-search-page-page-1 accept-charsetUTF-8> div classjs-form-item form-item js-form-type-textfield form-item-search-api-fulltext js-form-item-search-api-fulltext> label foredit-search-api-fulltext>Fulltext search/label> input placeholderLooking for... data-drupal-selectoredit-search-api-fulltext typetext idedit-search-api-fulltext namesearch_api_fulltext value size30 maxlength128 classform-text /> div idedit-search-api-fulltext--description classdescription> Search /div> /div>div data-drupal-selectoredit-actions classform-actions js-form-wrapper form-wrapper idedit-actions>input data-drupal-selectoredit-submit-search-page typesubmit idedit-submit-search-page valueApply classbutton js-form-submit form-submit />/div>/form> i idform-search-icon classfas fa-search>/i>/div> /div> /div> div> div data-drupal-messages-fallback classhidden>/div>div idreport-pop> div classpop-up-content> div classpop-up-inner> div idclose-pop> div classtriangle>/div> i classfal fa-times>/i> /div> div classtext> div classinner-container>h2>Report adverse events:/h2>p>Adverse events should be reported to the Vifor Pharma group.br>a hrefmailto:safety@viforpharma.com>safety@viforpharma.com/a>/p>/div> div classfull-btn-holder> a hrefmailto:safety@viforpharma.com> div classfull-btn green-full> span> Send email img src/themes/custom/veltassa_global/images/green-arrow.png>/span> div classwhite-btn-part>/div> /div> /a> /div> /div> /div> /div>/div>div idblock-veltassa-global-content> div idhome-page> div classherospace> div classherospace-image stylebackground-image: url(/sites/multisite/veltassa/files/2020-12/herospace-min.png)> div classherospace-text> p>Providing sustained, around the clock control of your patients’ Ksup>+/sup>, and proven to enable guideline-recommended RAASi treatment, Veltassasup>®/sup> is reliable and easy to use with no sodium-associated risksup>1–7/sup>/p> div classfull-btn-holder> a href/global/about> div classfull-btn green-full> span> Find out more about the reliability and ease of use of Veltassasup>®/sup>/span> img src/themes/custom/veltassa_global/images/green-arrow.png> div classwhite-btn-part>/div> /div> /a> /div> /div> div classicon-scroll onclicksmoothScroll(document.querySelector(#k-control))> div classwheel>/div> i classfal fa-chevron-down icon-scroll-arrow arrow_1>/i> i classfal fa-chevron-down icon-scroll-arrow arrow_2>/i> /div> /div> /div> div idk-control stylebackground-image: url(/themes/custom/veltassa_global/images/backgrounds/BG2.png)> div classhome-inner> h2> Ksup>+/sup> control with Veltassasup>®/sup>span>/span>/h2> /div> div classwhite-bg-half> div classk-control-inner> div classk-control-container> div classlist> ul>li>Chronic hyperkalaemia is a serious medical condition associated with high morbidity and mortality.sup>8-13/sup>/li>li>RAASi treatment exacerbates the risk of hyperkalaemia.sup>14/sup>/li>li>Guideline-recommended RAASi treatment improves outcomes in patients with CKD and heart failure.sup>14-24/sup>/li>li>Stopping or discontinuing RAASi is associated with worse outcomessup>25/sup>/li>/ul> /div> div classgreen-boxes> div classeach-box> div classgreen-tri>h4>Reliable/h4>div classtriangle> /div>/div>ul>li>Proven to enable guideline-recommended RAASi treatmentsup>1,4,5,20,26/sup>/li>li>Reduces Ksup>+/sup> levels from the first dosesup>3/sup>/li>li>Sustained long-term Ksup>+/sup> controlsup>2/sup>/li>/ul>/div> div classeach-box> div classgreen-tri>h4>Easybr>to use/h4>div classtriangle> /div>/div>ul>li>Once-daily dosing from the startsup>7/sup>/li>li>Can be taken with apple or cranberry juice to suit individual tastessup>7/sup>/li>/ul>/div> div classeach-box> div classgreen-tri>h4>No Nasup>+/sup>br>risk/h4>div classtriangle> /div>/div>ul>li>No additional CV and renal risk due to Nasup>+6/sup>/li>/ul>/div> /div> div classicon-and-text> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon1.png data-entity-uuid0c1d3ae0-c2e7-4c9e-866a-68223689db7b data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Sustained Ksup>+/sup> control inbr>up to 95% of patientssup>2/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon2.png data-entity-uuid349ab048-0736-4710-953f-7a0a79f23bea data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Effective regardlessbr>of HK severitysup>1/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon3.png data-entity-uuid26d186cd-91c2-4b5c-a5d8-9a19422052fa data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Round the clockbr>protectionsup>3/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon4.png data-entity-uuid47a20daa-a1a8-4027-9ac1-fb1bcafb2400 data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>RAASibr>enablementsup>1,4,5,20,26/sup>/h5>/div> /div> div classgreen-btn-img-box> div classleft-triangle triangle>/div> div classright-triangle triangle>/div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/icon5.png width116 height116 alticon typeoffoaf:Image /> div classfull-btn-holder> a href/global/what-is-hyperkalaemia> div classfull-btn green-full> span> Understand why reliable K+ control is important/span> img src/themes/custom/veltassa_global/images/green-arrow.png> div classwhite-btn-part>/div> /div> /a> /div> /div> /div> /div> /div> /div> div idworks stylebackground-image: url(/themes/custom/veltassa_global/images/backgrounds/BG3.png)> div classwhite-bg-half> div classhome-inner> div classworks-container> div classpart> h2> HOW VELTASSAsup>®/sup> WORKSspan>/span>/h2> div classlist> ul>li>Veltassasup>®/sup> exchanges Ksup>+/sup> for Casup>2+/sup>, making it suitable for patients who cannot tolerate even a small increase in Nasup>+/sup> load.sup>6,7/sup>/li>li>Veltassasup>®/sup> is specifically designed to act in the colon where the concentration of Ksup>+/sup> is highest.sup>6,7/sup>/li>/ul> /div> /div> div classpart> div classvideo-container> div classtabs> div classtab-name> MOA video div classtriangle>/div> /div> /div> div classvideo> p> /p>div stylemax-width:100%;>style> video-js.video-js.vjs-fluid:not(.vjs-audio-only-mode) { padding-top: 100%; } /style>video-js classvjs-fluid data-account5987230675001 data-playerdefault data-embeddefault controls data-video-id6370632936112 data-playlist-id data-application-id>/video-js>/div>script srchttps://players.brightcove.net/5987230675001/default_default/index.min.js>/script>p> /p> /div> /div> /div> div classicon-and-text> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon6.png data-entity-uuidad8dbac0-357c-4017-8284-9efe1a8cc9a2 data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Hypokalaemia has notbr>been identified as anbr>ADR for Veltassasup>®7/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon7.png data-entity-uuiddb6d91fa-7a53-45bd-b023-0ecb5fd3284d data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>No dose-related oedemabr>observed in over 52br>weeks of treatmentsup>2/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon8.png data-entity-uuidad45655b-0b62-436c-9b69-68aa7e4ca6c6 data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Positive risk/benefitbr>profile in clinical trialsbr>and real world practicesup>7/sup>/h5>/div> /div> div classgreen-btn-img-box> div classleft-triangle triangle>/div> div classright-triangle triangle>/div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/icon9.png width116 height116 alticon typeoffoaf:Image /> div classfull-btn-holder> a href/global/about> div classfull-btn green-full> span> Learn more about Veltassasup>®/sup>/span> img src/themes/custom/veltassa_global/images/green-arrow.png> div classwhite-btn-part>/div> /div> /a> /div> /div> /div> /div> /div> /div> div iddosing stylebackground-image: url(/themes/custom/veltassa_global/images/backgrounds/BG4.png)> div classwhite-bg-half> div classhome-inner> div classdosing-container> h2> Simple and easy once-daily dosingspan>/span>/h2> div classinstructions-box> div classtriangle>/div> div classstep> div classnumber>1div classnumber-triangle>/div> /div> p> MIX/p> /div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/Step1-MIX.png width180 height180 altInformation on how to take Veltassa: Step 1 MIX typeoffoaf:Image /> div classline>/div> div classstep-text> p>Mix 3 tablespoons of water with an entire sachet of Veltassasup>®/sup>, then stir/p> /div> /div> div classinstructions-box> div classtriangle>/div> div classstep> div classnumber>2div classnumber-triangle>/div> /div> p> ADD/p> /div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/Step2-ADD.png width180 height180 altInformation on how to take Veltassa: Step 2 ADD typeoffoaf:Image /> div classline>/div> div classstep-text> p>Add another 3 tablespoons of water and stir thoroughly. The powder will not dissolve and the mixture will look cloudy/p> /div> /div> div classinstructions-box> div classtriangle>/div> div classstep> div classnumber>3div classnumber-triangle>/div> /div> p> DRINK/p> /div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/Step3-DRINK.png width180 height180 altInformation on how to take Veltassa: Step 3 DRINK typeoffoaf:Image /> div classline>/div> div classstep-text> p>Drink immediately. If powder remains in the glass after drinking, repeat steps 2 and 3 to ensure the entire dose is taken/p> /div> /div> div classinline-list list> ul>li>The recommended starting dose of 1 x 8.4 g sachet per day is effective in >90% of patientssup>7,27/sup>/li>li>Veltassasup>®/sup> can be taken with apple or cranberry juice to suit individual tastessup>7/sup>/li>/ul> /div> div classgreen-btn-img-box> div classleft-triangle triangle>/div> div classright-triangle triangle>/div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/icon10.png width116 height116 alticon typeoffoaf:Image /> div classfull-btn-holder> a href/global/clinical-experience> div classfull-btn green-full> span> Read up on the clinical experience with Veltassasup>®/sup>/span> img src/themes/custom/veltassa_global/images/green-arrow.png> div classwhite-btn-part>/div> /div> /a> /div> /div> /div> /div> /div> /div> div idreferences> div classreferences-button-holder> div classreferences-button> div classopen-ref> p>References & footnotes/p> div classwhite-part>/div> /div> /div> /div> div classreferences-text> p>strong>ADR/strong>, adverse drug reaction; strong>Casup>2+/sup>/strong>, calcium ions; strong>CKD/strong>, chronic kidney disease; strong>CV/strong>, cardiovascular; strong>HK/strong>, hyperkalaemia; strong>Ksup>+/sup>/strong>, potassium ions; strong>MOA/strong>, mechanism of action; strong>Nasup>+/sup>/strong>, sodium ions; strong>RAASi/strong>, renin-angiotensin-aldosterone system inhibitors./p>h6>Footnotes:/h6>p>Veltassasup>®/sup> is indicated for the treatment of hyperkalaemia in adults.sup>7/sup>/p>h6>References:/h6>p>strong>1./strong> Weir MR, em>et al. N Engl J Med/em> 2015;372(3):211–21. strong>2./strong> Bakris GL, em>et al. JAMA/em> 2015;314(2):151–61. strong>3./strong> Bushinsky DA, em>et al. Kidney Int /em>2015;88:1427–33. strong>4./strong> Pitt B, em>et al. Eur Heart J/em> 2011;32:820–8. strong>5./strong> Agarwal R, em>et al. Lancet /em>2019;394(10208):1540−50. strong>6./strong> Li L, em>et al. J Card Pharmacol Ther/em> 2016;21(5):456–65. strong>7./strong> Veltassasup>®/sup> EU SmPC, 2019. strong>8./strong> Di Lullo L, em>et al. Cardiorenal Med/em> 2019;9(1):8−21. strong>9./strong> Rastegar A, Soleimani M. em>Postgrad Med J /em>2001;77(914):759−64. strong>10./strong> Kjeldsen KP, Schmidt TA. em>Eur Heart J/em> 2019;21(Suppl A):A2−A5. strong>11./strong> Collins AJ, em>et al. Am J Nephrol /em>2017;46(3):213−21. strong>12./strong> Kovesdy CP, em>et al. Eur Heart J /em>2018;39(17):1535−42. strong>13./strong> Rossignol P, em>et al. Clin Kidney J /em>2020;13:714−9. strong>14./strong> Palmer BF, em>et al. N Engl J Med /em>2004;351:585–92. strong>15./strong> KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. em>Kidney Int/em> 2020;98(Suppl 4S):S1–S116. strong>16./strong> KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. em>Kidney Int Suppl /em>2013;3:1–150. strong>17./strong> National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. 2004. Available at: kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_bp/index.htm (accessed July 2020). strong>18. /strong>Heart Outcomes Prevention Evaluation Study Investigators. em>Lancet /em>2000;355(9200):253−9. strong>19./strong> SOLVD Investigators. em>N Engl J Med/em> 1991;325(5):293−302. strong>20./strong> Desai AS, em>et al. J Am Coll Cardiol /em>2007;50(20):1959−66. strong>21./strong> Pitt B, em>et al. N Engl J Med/em> 1999;341(10):709−17. strong>22./strong> Zannad F,em> et al. N Engl J Med /em>2011;364:11–21. strong>23./strong> McMurray JJ, em>et al. N Engl J Med/em> 2014;371(11):993−1004. strong>24. /strong>Solomon SD, em>et al. N Engl J Med /em>2019;381(17):1609−20. strong> 25. /strong>Epstein M, em>et al. Am J Manag Care /em>2015;21(11 Suppl):S212−S220. strong>26. /strong>Kovesdy CP,em> et al. Postgrad Med /em>2020;132:176–83. strong>27./strong> Data on file. Healthcare Analytics (SHA), a Symphony Health Solutions Corporation (February 2019). /p>/div> /div>/div> /div> /div> div idfooter> div idcontact> div classtriangle>/div> div classcontact-inner> h2> Contact a Vifor medical representative/h2> div classline>/div> p>To learn more about hyperkalaemia management with Veltassasup>®/sup>, please contact us./p> div classfull-btn-holder> a classdevent_action data-event-action data-event-categoryInternal Link Click data-event-label/global/optin-form href/global/optin-form> div classfull-btn blue-full> span> Contact us/span> img src/themes/custom/veltassa_global/images/blue-arrow.png/> div classwhite-btn-part>/div> /div> /a> /div> /div>/div>div classfooter-info> a hrefhttps://www.viforpharma.com/ classfooter-logo devent_action data-event-action data-event-categoryExternal Link Click data-event-labelhttps://www.viforpharma.com/ target_blank> img loadinglazy src/sites/multisite/veltassa/files/2020-12/VP_Logo.png width121 height36 altlogo typeoffoaf:Image />/a> div classboxes> div classinfo-box> h3>Address/h3>p>Veltassa/p>p>Rechenstrasse 37,br>9014 St. Gallen,br>Switzerland/p>/div> div classinfo-box> h3>Stay in touch/h3>p>Keep up to date on social media orbr>Contact us with any other Information/p>p>T: +41 (0) 58 851 8000br>F: +41 (0) 58 851 8001br>a hrefmailto:medinfo@viforpharma.com>medinfo@viforpharma.com/a>/p>/div> div classinfo-box> h3>Sign up for alerts/h3>p>Be notified of any news, reports orbr>updates straight to your email address/p>p>a href/global/optin-form>strong>i classfal fa-envelope> /i>Sign up and get the latest news/strong>/a>/p>/div> /div>/div>nav rolenavigation aria-labelledbyblock-footer-menu idblock-footer> h2 classvisually-hidden idblock-footer-menu>Footer/h2> ul> li> a href/global/what-is-hyperkalaemia data-drupal-link-system-pathnode/351>What is Hyperkalaemia?/a> ul> li> a href/global/what-is-hyperkalaemia?sectionhomeostasis data-drupal-link-query{"section":"homeostasis"} data-drupal-link-system-pathnode/351>K+ Homeostasis is critical/a> /li> li> a href/global/what-is-hyperkalaemia?sectioncauses data-drupal-link-query{"section":"causes"} data-drupal-link-system-pathnode/351>What causes hyperkalaemia? /a> /li> li> a href/global/what-is-hyperkalaemia?sectioncondition data-drupal-link-query{"section":"condition"} data-drupal-link-system-pathnode/351>HK is a serious medical condition/a> /li> li> a href/global/what-is-hyperkalaemia?sectionrisk data-drupal-link-query{"section":"risk"} data-drupal-link-system-pathnode/351>CKD and HF patients are at Risk of HK/a> /li> /ul> /li> li> a href/global/hk-challenge-in-ckd data-drupal-link-system-pathnode/331>HK Challenge in CKD/a> ul> li> a href/global/hk-challenge-in-ckd?sectionckd-therapy data-drupal-link-query{"section":"ckd-therapy"} data-drupal-link-system-pathnode/331>RAASI therapy is vital/a> /li> li> a href/global/hk-challenge-in-ckd?sectionckd-exacerbated data-drupal-link-query{"section":"ckd-exacerbated"} data-drupal-link-system-pathnode/331>HK Risk is exacerbated by RAASI/a> /li> li> a href/global/hk-challenge-in-ckd?sectionckd-suboptimal data-drupal-link-query{"section":"ckd-suboptimal"} data-drupal-link-system-pathnode/331>HK leads to suboptimal RAASI use/a> /li> li> a href/global/hk-challenge-in-ckd?sectionckd-treatment-option data-drupal-link-query{"section":"ckd-treatment-option"} data-drupal-link-system-pathnode/331>Current treatment options are limited/a> /li> /ul> /li> li> a href/global/hk-challenge-in-hf data-drupal-link-system-pathnode/336>HK Challenge in HF/a> ul> li> a href/global/hk-challenge-in-hf?sectionhf-therapy data-drupal-link-query{"section":"hf-therapy"} data-drupal-link-system-pathnode/336>RAASI therapy is vital/a> /li> li> a href/global/hk-challenge-in-hf?sectionhf-risk data-drupal-link-query{"section":"hf-risk"} data-drupal-link-system-pathnode/336>HK Risk is exacerbated by RAASI/a> /li> li> a href/global/hk-challenge-in-hf?sectionhf-suboptimal data-drupal-link-query{"section":"hf-suboptimal"} data-drupal-link-system-pathnode/336>HK leads to suboptimal RAASI use/a> /li> li> a href/global/hk-challenge-in-hf?sectionhf-treatment data-drupal-link-query{"section":"hf-treatment"} data-drupal-link-system-pathnode/336>Current treatment options are limited/a> /li> /ul> /li> li> a href/global/about classlittle-sup data-drupal-link-system-pathnode/291>About Veltassa/a> ul> li> a href/global/about?sectionabout-what-is classlittle-sup-question data-drupal-link-query{"section":"about-what-is"} data-drupal-link-system-pathnode/291>What is Veltassa/a> /li> li> a href/global/about?sectionabout-mechanism classlittle-sup data-drupal-link-query{"section":"about-mechanism"} data-drupal-link-system-pathnode/291>Mechanism of action of Veltassa/a> /li> li> a href/global/about?sectionabout-use data-drupal-link-query{"section":"about-use"} data-drupal-link-system-pathnode/291>Easy to use/a> /li> /ul> /li> li> a href/global/clinical-experience data-drupal-link-system-pathnode/296>Clinical Experience/a> ul> li> a href/global/clinical-experience?sectionexperience-reliable data-drupal-link-query{"section":"experience-reliable"} data-drupal-link-system-pathnode/296>Reliable K+ Control /a> /li> li> a href/global/clinical-experience?sectionexperience-proven data-drupal-link-query{"section":"experience-proven"} data-drupal-link-system-pathnode/296>RAASI enablement/a> /li> li> a href/global/clinical-experience?sectionexperience-safety data-drupal-link-query{"section":"experience-safety"} data-drupal-link-system-pathnode/296>Favourable safety and tolerability/a> /li> li> a href/global/clinical-experience?sectionexperience-programme data-drupal-link-query{"section":"experience-programme"} data-drupal-link-system-pathnode/296>Clinical programme/a> /li> /ul> /li> li> a href/global/resources data-drupal-link-system-pathnode/346>Resources/a> ul> li> a href/global/resources?sectionresources-for-you data-drupal-link-query{"section":"resources-for-you"} data-drupal-link-system-pathnode/346>For you/a> /li> li> a href/global/resources?sectionresources-for-patients data-drupal-link-query{"section":"resources-for-patients"} data-drupal-link-system-pathnode/346>For your patients/a> /li> /ul> /li> /ul> /nav>div classfooter-text> div classdisclaimer> p>The information and materials for Veltassa contained in this website were prepared based on the EU SmPC. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC)./p>/div> div classtext> div classinner-container>p>Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd, a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and 0M Pharma. For more information about Vifor Pharma, please visit a hrefhttps://www.viforpharma.com/>www.viforpharma.com/a>/p>p>This site does not provide medical advice and may not be relied upon by any healthcare practitioner in exercising his or her professional judgement in the practice of medicine. The information provided herein is provided for general educational purposes only, and is not to be used or relied on for any diagnostic or treatment purposes. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed; rather the material is intended to present an approach, view, statement or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. VFMCRP makes no warranties or representations as to the site’s accuracy, completeness or up-to-date information. All users agree that access to this site is at their own risk, and that neither VFMCRP any party involved in creating or delivering this site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if VFMCRP has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this site. This limitation includes damages to, or for any viruses that may infect your computer equipment.br>© 2019 Vifor Fresenius Medical Care Renal Pharma/p>/div>/div> div classbottom-links> div classcontainer> div classlinks> a href/global/terms target_blank>Terms of use/a> a hrefhttps://privacy.csl.com/ target_blank>Privacy policy/a> a href/global/cookie-settings target_blank>Cookie policy/a> a hrefhttps://www.ema.europa.eu/en/medicines/human/EPAR/veltassa target_blank>Prescribing information/a> span classot-sdk-show-settings>COOKIE SETTINGS/span> /div> div classdate> HQ-PAT-2000046 | Date of preparation: December 2020/div> /div> /div>/div> /div> /div> script typeapplication/json data-drupal-selectordrupal-settings-json>{path:{baseUrl:\/,pathPrefix:,currentPath:node\/341,currentPathIsAdmin:false,isFront:true,currentLanguage:en},pluralDelimiter:\u0003,suppressDeprecationErrors:true,ajaxTrustedUrl:{\/search:true},user:{uid:0,permissionsHash:a0c2ac8405ada1d374bc24ef406722bdf880de0d9f38fc029f1698a4e5ed5f14}}/script>script srchttps://code.jquery.com/jquery-3.6.4.min.js>/script>script src/sites/multisite/veltassa/files/js/js_GJDDcyAMQQrNpqAB-EFr_Krt6Z9inqK6HuBGDl30ndo.js?scopefooter&delta1&languageen&themeveltassa_global&includeeJzLKixNLaqMT8kvz0svSkxJ1c-CCOSkpicmV-qUpeaUJBYXJ8an5-QnJeboQyjdrGIAi0wWZw>/script>script src/themes/custom/veltassa_global/js/lib/custom.js?v1&t9989k defer>/script>script src/sites/multisite/veltassa/files/js/js_zmIjmy5tLxq16RyXZ_b4jUdkE6ndkdU8XulXTcmgqRs.js?scopefooter&delta3&languageen&themeveltassa_global&includeeJzLKixNLaqMT8kvz0svSkxJ1c-CCOSkpicmV-qUpeaUJBYXJ8an5-QnJeboQyjdrGIAi0wWZw>/script>/js-bottom-placeholder> /body>/html>
Port 443
HTTP/1.1 200 OKDate: Fri, 13 Feb 2026 23:35:14 GMTContent-Type: text/html; charsetUTF-8Transfer-Encoding: chunkedConnection: keep-aliveServer: Cache-Control: must-revalidate, no-cache, privateContent-language: enX-Content-Type-Options: nosniffX-Frame-Options: SAMEORIGINExpires: Sun, 19 Nov 1978 05:00:00 GMTX-Dynamic-Cache: MISSX-Cache: HIT !DOCTYPE html>html langen dirltr prefixcontent: http://purl.org/rss/1.0/modules/content/ dc: http://purl.org/dc/terms/ foaf: http://xmlns.com/foaf/0.1/ og: http://ogp.me/ns# rdfs: http://www.w3.org/2000/01/rdf-schema# schema: http://schema.org/ sioc: http://rdfs.org/sioc/ns# sioct: http://rdfs.org/sioc/types# skos: http://www.w3.org/2004/02/skos/core# xsd: http://www.w3.org/2001/XMLSchema# > head> !-- Google Tag Manager --> script>(function(w,d,s,l,i){wlwl||;wl.push({gtm.start: new Date().getTime(),event:gtm.js});var fd.getElementsByTagName(s)0, jd.createElement(s),dll!dataLayer?&l+l:;j.asynctrue;j.src https://www.googletagmanager.com/gtm.js?id+i+dl;f.parentNode.insertBefore(j,f); })(window,document,script,dataLayer,GTM-MSRZ698);/script> !-- End Google Tag Manager --> meta charsetutf-8 />meta namedescription contentVeltassa® is a reliable and easy to use hyperkalaemia treatment with no sodium-associated risk. />meta namerobots contentindex />link relshortlink hrefhttps://www.veltassa.com/ />link relcanonical hrefhttps://www.veltassa.com/ />meta propertyog:site_name contentVeltassa Global />meta propertyog:url contenthttps://www.veltassa.com/global />meta propertyog:title contentVeltassa Global | Home />meta propertyog:description contentVeltassa® is a reliable and easy to use hyperkalaemia treatment with no sodium-associated risk. />meta nameMobileOptimized contentwidth />meta nameHandheldFriendly contenttrue />meta nameviewport contentwidthdevice-width, initial-scale1.0 />script srchttps://cdn.cookielaw.org/scripttemplates/otSDKStub.js data-document-languagetrue typetext/javascript charsetUTF-8 data-domain-scriptbf1aaf89-6c64-444d-914f-e15ac0a2c72d>/script>script typetext/javascript> function OptanonWrapper() { }/script>link relicon href/themes/custom/veltassa_global/favicon.ico typeimage/vnd.microsoft.icon />link relalternate hreflangen hrefhttps://www.veltassa.com/ />link relalternate hreflangch-de hrefhttps://www.veltassa.com/ch-de />link relalternate hreflangch-fr hrefhttps://www.veltassa.com/ch-fr />/head-placeholder> title>Veltassa Global | Home/title> link relstylesheet mediaall href/sites/multisite/veltassa/files/css/css_skRohsATvY4NnKMFuYiPrAFL-zg2zfuaKrfyt-vUaH0.css?delta0&languageen&themeveltassa_global&includeeJwrriwuSc3VT0osTtUpS80pSSwuToxPz8lPSszRh1C6ycXFACYjDuU />link relstylesheet mediaall href/sites/multisite/veltassa/files/css/css_vyrW_mFVdeVaCXgoqIXoLpODuPkKY8GCxzVkpSi6JC0.css?delta1&languageen&themeveltassa_global&includeeJwrriwuSc3VT0osTtUpS80pSSwuToxPz8lPSszRh1C6ycXFACYjDuU />/css-placeholder> /js-placeholder> /head> body classglobal language_en class> !-- Google Tag Manager (noscript) --> noscript> iframe srchttps://www.googletagmanager.com/ns.html?idGTM-MSRZ698 height0 width0 styledisplay:none;visibility:hidden>/iframe> /noscript> !-- End Google Tag Manager (noscript) --> div classdialog-off-canvas-main-canvas data-off-canvas-main-canvas> div> div idlogin-popup> div idlogin-popup-modal-1 classpopup-modal> div classtitle-row> h4>Help us guide you to the right place/h4> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div classus-row> h5>I reside in the United States/h5> a href/patient/>Visit the US siteimg src/themes/custom/veltassa_global/images/dark_arrow.png>/a> /div> hr> div classrow>I do not reside in the United States/div> div classbig-buttons-row> div idiam-hcp-button classlinkto big-button data-hcptrue data-linktologin-popup-modal-2> i data-hcptrue classfal fa-stethoscope>/i> h4 data-hcptrue>I am a health/h4> h4 data-hcptrue>care professional/h4> p data-hcptrue>This is me, continueimg src/themes/custom/veltassa_global/images/dark_arrow.png>/p> /div> div idiam-not-hcp-button data-hcpfalse classlinkto big-button data-linktologin-popup-modal-3> i data-hcpfalse classfal fa-user>/i> h4 data-hcpfalse>I am span>not/span> a health/h4> h4 data-hcpfalse>care professional/h4> p data-hcpfalse>This is me, continueimg src/themes/custom/veltassa_global/images/dark_arrow.png>/p> /div> /div> /div> div idlogin-popup-modal-2 classpopup-modal> div classtitle-row> h4>Help us guide you to the right place/h4> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div idconfirm-big-button classbig-buttons-row> div idiam-hcp-button classbig-button> i classfal fa-stethoscope>/i> h4>I am a health/h4> h4>care professional/h4> /div> /div> div classcountries-row> div classcheckbox data-checkednone> i classfar fa-check>/i> /div> p>I am practicing from:/p> div classcountry-selector> div classcurrent-country> img src/themes/custom/veltassa_global/images/countries/austria.png altAustrian flag/> p>Austria/p> i classfar fa-chevron-down>/i> /div> ul classdefault-country-selector> li classselected-country data-valueaustria data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/austria-min.png altAustrian flag/> p>Austria/p> /li> li data-valuebelgium data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/belgium-min.png altBelgium flag/> p>Belgium/p> /li> li data-valuegermany data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/germany-min.png altGermany flag/> p>Germany/p> /li> li data-valueireland data-validatornone> img src/themes/custom/veltassa_global/images/countries/ireland-min.png altIreland flag/> p>Ireland/p> /li> li data-valueitaly data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/italy-min.png altItaly flag/> p>Italy/p> /li> li data-valuenetherlands data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/netherlands-min.png altNetherlands flag/> p>Netherlands/p> /li> li data-valueportugal data-validatordoccheck-modal> img src/themes/custom/veltassa_global/images/countries/portugal-min.png altPortugal flag/> p>Portugal/p> /li> li data-valuespain data-validatornone> img src/themes/custom/veltassa_global/images/countries/spain-min.png altSpain flag/> p>Spain/p> /li> li data-valueswitzerland data-validatorswissrx-modal data-swissyes> img src/themes/custom/veltassa_global/images/countries/switzerland-min.png altSwitzerland flag/> p>Switzerland/p> /li> li data-valueother data-validatornotavailable-modal> p>Other/p> /li> /ul> /div> /div> hr> div classbuttons-row> div classbtn linkto back-button data-linktologin-popup-modal-1>Back to options/div> div classbtn linkto locked-button data-linktocustom>Continue/div> div classcontinue-button-cover>/div> /div> /div> div idlogin-popup-modal-3 classpopup-modal> div classtitle-row> h4>Help us guide you to the right place/h4> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div idconfirm-big-button classbig-buttons-row> div idiam-not-hcp-button classbig-button> i classfal fa-user>/i> h4>I am span>not/span> a health/h4> h4>care professional/h4> /div> /div> div classcountries-row> div classcheckbox data-checkednone> i classfar fa-check>/i> /div> p>I am residing in:/p> div classcountry-selector> div classcurrent-country> img src/themes/custom/veltassa_global/images/countries/austria.png altAustrian flag/> p>Austria/p> i classfar fa-chevron-down>/i> /div> ul classdefault-country-selector> li classselected-country data-valueaustria> img src/themes/custom/veltassa_global/images/countries/austria-min.png altAustrian flag/> p>Austria/p> /li> li data-valuebelgium> img src/themes/custom/veltassa_global/images/countries/belgium-min.png altBelgium flag/> p>Belgium/p> /li> li data-valuegermany> img src/themes/custom/veltassa_global/images/countries/germany-min.png altGermany flag/> p>Germany/p> /li> li data-valueireland> img src/themes/custom/veltassa_global/images/countries/ireland-min.png altIreland flag/> p>Ireland/p> /li> li data-valueitaly> img src/themes/custom/veltassa_global/images/countries/italy-min.png altItaly flag/> p>Italy/p> /li> li data-valuenetherlands> img src/themes/custom/veltassa_global/images/countries/netherlands-min.png altNetherlands flag/> p>Netherlands/p> /li> li data-valueportugal> img src/themes/custom/veltassa_global/images/countries/portugal-min.png altPortugal flag/> p>Portugal/p> /li> li data-valuespain> img src/themes/custom/veltassa_global/images/countries/spain-min.png altSpain flag/> p>Spain/p> /li> li data-valueswitzerland> img src/themes/custom/veltassa_global/images/countries/switzerland-min.png altSwitzerland flag/> p>Switzerland/p> /li> li data-valueother> p>Other/p> /li> /ul> /div> /div> hr> div classbuttons-row> div classbtn linkto back-button data-linktologin-popup-modal-1>Back to options/div> a classbtn locked-button hrefhttps://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor#main-content-area>Continue/a> div classcontinue-button-cover>/div> /div> /div> div iddoccheck-modal classpopup-modal> div classtitle-row> div classback-button-on-top linkto data-linktologin-popup-modal-2> i classfas fa-chevron-left>/i> h4 data-i18nbackTo>Zurück zu den Optionen/h4> /div> i classfal fa-times> div classclose-popup data-i18nchoseOption>Bitte wählen Sie eine der folgenden Optionen!/div> /i> /div> form actionhttps://login.doccheck.com/ methodpost target_top> input typehidden namelogin_id value2000000016781> input typehidden namedc_iframe_referer valuehttps://veltassa.com/activated> input typehidden namestrDcLanguage valuede data-i18nlangCode> input typehidden nameintDcLanguageId value148> input typehidden nameintLoginVersion value3> input typehidden namestrDesignVersion valuelogin_xl> input typehidden nameintLogoutSwitch value0> div classintro-part> img src/themes/custom/veltassa_global/images/doccheck-logо.png altDoc Check Logo /> p data-i18nintro>Wenn Sie Mitglied der Community der medizinischen Fachkräfte sind, melden Sie sich bitte an./p> /div> div classinput-part> input typetext nameusername iddc_username autocapitalizeoff autocorrectoff placeholderBenutzername autocompleteoff data-i18nusername /> input typepassword namepassword iddc_password autocapitalizeoff autocorrectoff placeholderPassword eingeben autocompleteoff data-i18npassword/> div iddoc-check-login onclickdocument.querySelector(#doccheck-modal form).submit(); data-i18nlogin>Einloggen/div> /div> div classdoccheck-links> a hrefhttps://www.doccheck.com/de/account/register/ data-i18naccess>Registrierung/a> a hrefhttps://www.doccheck.com/de/account/password/reminder/ data-i18npasswordForgotten>Passwort vergessen?/a> /div> /form> /div> div idswissrx-modal classpopup-modal> div classtitle-row> div classback-button-on-top linkto data-linktologin-popup-modal-2> i classfas fa-chevron-left>/i> h4>Back to options/h4> /div> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div classintro-part> img src/themes/custom/veltassa_global/images/swissrx-logo.png altSwiss Rx logo /> p>Bitte verwenden Sie als Benutzernamen die E-Mail Adresse, welche Sie bei der Registration angegeben hatten. Falls Sie das Passwort vergessen haben, können Sie sich einen Reaktivierungslink zustellen lassen. Alternativ ist für bereits registrierte Health Professionals auch eine Anmeldung mit der HPC-Card von FMH oder pharmaSuisse möglich./p> /div> div classinput-part> form nameformPost actionhttps://swiss-rx-login.ch/ methodpost> input typehidden nameGLN idGLN value7601001001862/> input typehidden nameBackURL idBackURL valuehttps://www.veltassa.com/login/validated/> input typehidden nameShowText idShowText valueViforPharm/> input typehidden nameLang idLang valueDE/> input typesubmit valueLog in> /form> div classswissrx-links> a hrefhttps://swiss-rx-login.ch/Account/LogOn>Passwort Vergessen/a> /div> /div> /div> div idnotavailable-modal classpopup-modal> div classtitle-row> i classfal fa-times> div classclose-popup>Please select one of the below options!/div> /i> /div> div classmodal-title-text>Veltassa is not available in your country,br>please proceed./div> hr> div classbuttons-row> div classbtn linkto back-button data-linktologin-popup-modal-1>Back to options/div> a classbtn continue-button hrefhttps://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor#main-content-area>Continue/a> /div> /div>/div> /div> div idheader> div classinner-header> a classheader-logo href/global data-event-actionClick data-event-categoryHeader data-event-labelHeader logo> img loadinglazy src/sites/multisite/veltassa/files/2024-02/veltassa_logo_new_3.png width372 height208 altVeltassa logo typeoffoaf:Image /> /a> div classtop-menu> div classbutton> a hrefhttps://www.ema.europa.eu/en/medicines/human/EPAR/veltassa>Prescribing Information/a>/div> div classbutton report-pop-button> Adverse Event Reportingi classfal fa-plus-square header-top-menu-element>/i>/div>/div>div classline>/div>div classsearch-menu-item> Searchi classfar fa-search search-icon>/i>/div>div classmobile-menu-btn> div classmenu-line long-menu-line>/div> div classmenu-line short-menu-line>/div>/div>nav rolenavigation aria-labelledbyblock-mainnavigation-menu idblock-mainnavigation> h2 classvisually-hidden idblock-mainnavigation-menu>Main navigation/h2> ul> li> a href/global/what-is-hyperkalaemia data-drupal-link-system-pathnode/351>What is Hyperkalaemia?/a> /li> li> a href/global/hk-challenge-in-ckd data-drupal-link-system-pathnode/331>HK Challenge in CKD/a> /li> li> a href/global/hk-challenge-in-hf data-drupal-link-system-pathnode/336>HK Challenge in HF/a> /li> li> a href/global/about data-drupal-link-system-pathnode/291>About Veltassa/a> /li> li> a href/global/clinical-experience data-drupal-link-system-pathnode/296>Clinical Experience/a> /li> li> a href/global/resources data-drupal-link-system-pathnode/346>Resources/a> /li> /ul> /nav>div idblock-searchform> form action/search methodget idviews-exposed-form-search-page-page-1 accept-charsetUTF-8> div classjs-form-item form-item js-form-type-textfield form-item-search-api-fulltext js-form-item-search-api-fulltext> label foredit-search-api-fulltext>Fulltext search/label> input placeholderLooking for... data-drupal-selectoredit-search-api-fulltext typetext idedit-search-api-fulltext namesearch_api_fulltext value size30 maxlength128 classform-text /> div idedit-search-api-fulltext--description classdescription> Search /div> /div>div data-drupal-selectoredit-actions classform-actions js-form-wrapper form-wrapper idedit-actions>input data-drupal-selectoredit-submit-search-page typesubmit idedit-submit-search-page valueApply classbutton js-form-submit form-submit />/div>/form> i idform-search-icon classfas fa-search>/i>/div> /div> /div> div> div data-drupal-messages-fallback classhidden>/div>div idreport-pop> div classpop-up-content> div classpop-up-inner> div idclose-pop> div classtriangle>/div> i classfal fa-times>/i> /div> div classtext> div classinner-container>h2>Report adverse events:/h2>p>Adverse events should be reported to the Vifor Pharma group.br>a hrefmailto:safety@viforpharma.com>safety@viforpharma.com/a>/p>/div> div classfull-btn-holder> a hrefmailto:safety@viforpharma.com> div classfull-btn green-full> span> Send email img src/themes/custom/veltassa_global/images/green-arrow.png>/span> div classwhite-btn-part>/div> /div> /a> /div> /div> /div> /div>/div>div idblock-veltassa-global-content> div idhome-page> div classherospace> div classherospace-image stylebackground-image: url(/sites/multisite/veltassa/files/2020-12/herospace-min.png)> div classherospace-text> p>Providing sustained, around the clock control of your patients’ Ksup>+/sup>, and proven to enable guideline-recommended RAASi treatment, Veltassasup>®/sup> is reliable and easy to use with no sodium-associated risksup>1–7/sup>/p> div classfull-btn-holder> a href/global/about> div classfull-btn green-full> span> Find out more about the reliability and ease of use of Veltassasup>®/sup>/span> img src/themes/custom/veltassa_global/images/green-arrow.png> div classwhite-btn-part>/div> /div> /a> /div> /div> div classicon-scroll onclicksmoothScroll(document.querySelector(#k-control))> div classwheel>/div> i classfal fa-chevron-down icon-scroll-arrow arrow_1>/i> i classfal fa-chevron-down icon-scroll-arrow arrow_2>/i> /div> /div> /div> div idk-control stylebackground-image: url(/themes/custom/veltassa_global/images/backgrounds/BG2.png)> div classhome-inner> h2> Ksup>+/sup> control with Veltassasup>®/sup>span>/span>/h2> /div> div classwhite-bg-half> div classk-control-inner> div classk-control-container> div classlist> ul>li>Chronic hyperkalaemia is a serious medical condition associated with high morbidity and mortality.sup>8-13/sup>/li>li>RAASi treatment exacerbates the risk of hyperkalaemia.sup>14/sup>/li>li>Guideline-recommended RAASi treatment improves outcomes in patients with CKD and heart failure.sup>14-24/sup>/li>li>Stopping or discontinuing RAASi is associated with worse outcomessup>25/sup>/li>/ul> /div> div classgreen-boxes> div classeach-box> div classgreen-tri>h4>Reliable/h4>div classtriangle> /div>/div>ul>li>Proven to enable guideline-recommended RAASi treatmentsup>1,4,5,20,26/sup>/li>li>Reduces Ksup>+/sup> levels from the first dosesup>3/sup>/li>li>Sustained long-term Ksup>+/sup> controlsup>2/sup>/li>/ul>/div> div classeach-box> div classgreen-tri>h4>Easybr>to use/h4>div classtriangle> /div>/div>ul>li>Once-daily dosing from the startsup>7/sup>/li>li>Can be taken with apple or cranberry juice to suit individual tastessup>7/sup>/li>/ul>/div> div classeach-box> div classgreen-tri>h4>No Nasup>+/sup>br>risk/h4>div classtriangle> /div>/div>ul>li>No additional CV and renal risk due to Nasup>+6/sup>/li>/ul>/div> /div> div classicon-and-text> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon1.png data-entity-uuid0c1d3ae0-c2e7-4c9e-866a-68223689db7b data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Sustained Ksup>+/sup> control inbr>up to 95% of patientssup>2/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon2.png data-entity-uuid349ab048-0736-4710-953f-7a0a79f23bea data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Effective regardlessbr>of HK severitysup>1/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon3.png data-entity-uuid26d186cd-91c2-4b5c-a5d8-9a19422052fa data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Round the clockbr>protectionsup>3/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon4.png data-entity-uuid47a20daa-a1a8-4027-9ac1-fb1bcafb2400 data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>RAASibr>enablementsup>1,4,5,20,26/sup>/h5>/div> /div> div classgreen-btn-img-box> div classleft-triangle triangle>/div> div classright-triangle triangle>/div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/icon5.png width116 height116 alticon typeoffoaf:Image /> div classfull-btn-holder> a href/global/what-is-hyperkalaemia> div classfull-btn green-full> span> Understand why reliable K+ control is important/span> img src/themes/custom/veltassa_global/images/green-arrow.png> div classwhite-btn-part>/div> /div> /a> /div> /div> /div> /div> /div> /div> div idworks stylebackground-image: url(/themes/custom/veltassa_global/images/backgrounds/BG3.png)> div classwhite-bg-half> div classhome-inner> div classworks-container> div classpart> h2> HOW VELTASSAsup>®/sup> WORKSspan>/span>/h2> div classlist> ul>li>Veltassasup>®/sup> exchanges Ksup>+/sup> for Casup>2+/sup>, making it suitable for patients who cannot tolerate even a small increase in Nasup>+/sup> load.sup>6,7/sup>/li>li>Veltassasup>®/sup> is specifically designed to act in the colon where the concentration of Ksup>+/sup> is highest.sup>6,7/sup>/li>/ul> /div> /div> div classpart> div classvideo-container> div classtabs> div classtab-name> MOA video div classtriangle>/div> /div> /div> div classvideo> p> /p>div stylemax-width:100%;>style> video-js.video-js.vjs-fluid:not(.vjs-audio-only-mode) { padding-top: 100%; } /style>video-js classvjs-fluid data-account5987230675001 data-playerdefault data-embeddefault controls data-video-id6370632936112 data-playlist-id data-application-id>/video-js>/div>script srchttps://players.brightcove.net/5987230675001/default_default/index.min.js>/script>p> /p> /div> /div> /div> div classicon-and-text> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon6.png data-entity-uuidad8dbac0-357c-4017-8284-9efe1a8cc9a2 data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Hypokalaemia has notbr>been identified as anbr>ADR for Veltassasup>®7/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon7.png data-entity-uuiddb6d91fa-7a53-45bd-b023-0ecb5fd3284d data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>No dose-related oedemabr>observed in over 52br>weeks of treatmentsup>2/sup>/h5>/div> div classsingle-box> p>img src/sites/multisite/veltassa/files/inline-images/icon8.png data-entity-uuidad45655b-0b62-436c-9b69-68aa7e4ca6c6 data-entity-typefile alticon width80 height80 loadinglazy>/p>h5>Positive risk/benefitbr>profile in clinical trialsbr>and real world practicesup>7/sup>/h5>/div> /div> div classgreen-btn-img-box> div classleft-triangle triangle>/div> div classright-triangle triangle>/div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/icon9.png width116 height116 alticon typeoffoaf:Image /> div classfull-btn-holder> a href/global/about> div classfull-btn green-full> span> Learn more about Veltassasup>®/sup>/span> img src/themes/custom/veltassa_global/images/green-arrow.png> div classwhite-btn-part>/div> /div> /a> /div> /div> /div> /div> /div> /div> div iddosing stylebackground-image: url(/themes/custom/veltassa_global/images/backgrounds/BG4.png)> div classwhite-bg-half> div classhome-inner> div classdosing-container> h2> Simple and easy once-daily dosingspan>/span>/h2> div classinstructions-box> div classtriangle>/div> div classstep> div classnumber>1div classnumber-triangle>/div> /div> p> MIX/p> /div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/Step1-MIX.png width180 height180 altInformation on how to take Veltassa: Step 1 MIX typeoffoaf:Image /> div classline>/div> div classstep-text> p>Mix 3 tablespoons of water with an entire sachet of Veltassasup>®/sup>, then stir/p> /div> /div> div classinstructions-box> div classtriangle>/div> div classstep> div classnumber>2div classnumber-triangle>/div> /div> p> ADD/p> /div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/Step2-ADD.png width180 height180 altInformation on how to take Veltassa: Step 2 ADD typeoffoaf:Image /> div classline>/div> div classstep-text> p>Add another 3 tablespoons of water and stir thoroughly. The powder will not dissolve and the mixture will look cloudy/p> /div> /div> div classinstructions-box> div classtriangle>/div> div classstep> div classnumber>3div classnumber-triangle>/div> /div> p> DRINK/p> /div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/Step3-DRINK.png width180 height180 altInformation on how to take Veltassa: Step 3 DRINK typeoffoaf:Image /> div classline>/div> div classstep-text> p>Drink immediately. If powder remains in the glass after drinking, repeat steps 2 and 3 to ensure the entire dose is taken/p> /div> /div> div classinline-list list> ul>li>The recommended starting dose of 1 x 8.4 g sachet per day is effective in >90% of patientssup>7,27/sup>/li>li>Veltassasup>®/sup> can be taken with apple or cranberry juice to suit individual tastessup>7/sup>/li>/ul> /div> div classgreen-btn-img-box> div classleft-triangle triangle>/div> div classright-triangle triangle>/div> img loadinglazy src/sites/multisite/veltassa/files/2020-12/icon10.png width116 height116 alticon typeoffoaf:Image /> div classfull-btn-holder> a href/global/clinical-experience> div classfull-btn green-full> span> Read up on the clinical experience with Veltassasup>®/sup>/span> img src/themes/custom/veltassa_global/images/green-arrow.png> div classwhite-btn-part>/div> /div> /a> /div> /div> /div> /div> /div> /div> div idreferences> div classreferences-button-holder> div classreferences-button> div classopen-ref> p>References & footnotes/p> div classwhite-part>/div> /div> /div> /div> div classreferences-text> p>strong>ADR/strong>, adverse drug reaction; strong>Casup>2+/sup>/strong>, calcium ions; strong>CKD/strong>, chronic kidney disease; strong>CV/strong>, cardiovascular; strong>HK/strong>, hyperkalaemia; strong>Ksup>+/sup>/strong>, potassium ions; strong>MOA/strong>, mechanism of action; strong>Nasup>+/sup>/strong>, sodium ions; strong>RAASi/strong>, renin-angiotensin-aldosterone system inhibitors./p>h6>Footnotes:/h6>p>Veltassasup>®/sup> is indicated for the treatment of hyperkalaemia in adults.sup>7/sup>/p>h6>References:/h6>p>strong>1./strong> Weir MR, em>et al. N Engl J Med/em> 2015;372(3):211–21. strong>2./strong> Bakris GL, em>et al. JAMA/em> 2015;314(2):151–61. strong>3./strong> Bushinsky DA, em>et al. Kidney Int /em>2015;88:1427–33. strong>4./strong> Pitt B, em>et al. Eur Heart J/em> 2011;32:820–8. strong>5./strong> Agarwal R, em>et al. Lancet /em>2019;394(10208):1540−50. strong>6./strong> Li L, em>et al. J Card Pharmacol Ther/em> 2016;21(5):456–65. strong>7./strong> Veltassasup>®/sup> EU SmPC, 2019. strong>8./strong> Di Lullo L, em>et al. Cardiorenal Med/em> 2019;9(1):8−21. strong>9./strong> Rastegar A, Soleimani M. em>Postgrad Med J /em>2001;77(914):759−64. strong>10./strong> Kjeldsen KP, Schmidt TA. em>Eur Heart J/em> 2019;21(Suppl A):A2−A5. strong>11./strong> Collins AJ, em>et al. Am J Nephrol /em>2017;46(3):213−21. strong>12./strong> Kovesdy CP, em>et al. Eur Heart J /em>2018;39(17):1535−42. strong>13./strong> Rossignol P, em>et al. Clin Kidney J /em>2020;13:714−9. strong>14./strong> Palmer BF, em>et al. N Engl J Med /em>2004;351:585–92. strong>15./strong> KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. em>Kidney Int/em> 2020;98(Suppl 4S):S1–S116. strong>16./strong> KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. em>Kidney Int Suppl /em>2013;3:1–150. strong>17./strong> National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. 2004. Available at: kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_bp/index.htm (accessed July 2020). strong>18. /strong>Heart Outcomes Prevention Evaluation Study Investigators. em>Lancet /em>2000;355(9200):253−9. strong>19./strong> SOLVD Investigators. em>N Engl J Med/em> 1991;325(5):293−302. strong>20./strong> Desai AS, em>et al. J Am Coll Cardiol /em>2007;50(20):1959−66. strong>21./strong> Pitt B, em>et al. N Engl J Med/em> 1999;341(10):709−17. strong>22./strong> Zannad F,em> et al. N Engl J Med /em>2011;364:11–21. strong>23./strong> McMurray JJ, em>et al. N Engl J Med/em> 2014;371(11):993−1004. strong>24. /strong>Solomon SD, em>et al. N Engl J Med /em>2019;381(17):1609−20. strong> 25. /strong>Epstein M, em>et al. Am J Manag Care /em>2015;21(11 Suppl):S212−S220. strong>26. /strong>Kovesdy CP,em> et al. Postgrad Med /em>2020;132:176–83. strong>27./strong> Data on file. Healthcare Analytics (SHA), a Symphony Health Solutions Corporation (February 2019). /p>/div> /div>/div> /div> /div> div idfooter> div idcontact> div classtriangle>/div> div classcontact-inner> h2> Contact a Vifor medical representative/h2> div classline>/div> p>To learn more about hyperkalaemia management with Veltassasup>®/sup>, please contact us./p> div classfull-btn-holder> a classdevent_action data-event-action data-event-categoryInternal Link Click data-event-label/global/optin-form href/global/optin-form> div classfull-btn blue-full> span> Contact us/span> img src/themes/custom/veltassa_global/images/blue-arrow.png/> div classwhite-btn-part>/div> /div> /a> /div> /div>/div>div classfooter-info> a hrefhttps://www.viforpharma.com/ classfooter-logo devent_action data-event-action data-event-categoryExternal Link Click data-event-labelhttps://www.viforpharma.com/ target_blank> img loadinglazy src/sites/multisite/veltassa/files/2020-12/VP_Logo.png width121 height36 altlogo typeoffoaf:Image />/a> div classboxes> div classinfo-box> h3>Address/h3>p>Veltassa/p>p>Rechenstrasse 37,br>9014 St. Gallen,br>Switzerland/p>/div> div classinfo-box> h3>Stay in touch/h3>p>Keep up to date on social media orbr>Contact us with any other Information/p>p>T: +41 (0) 58 851 8000br>F: +41 (0) 58 851 8001br>a hrefmailto:medinfo@viforpharma.com>medinfo@viforpharma.com/a>/p>/div> div classinfo-box> h3>Sign up for alerts/h3>p>Be notified of any news, reports orbr>updates straight to your email address/p>p>a href/global/optin-form>strong>i classfal fa-envelope> /i>Sign up and get the latest news/strong>/a>/p>/div> /div>/div>nav rolenavigation aria-labelledbyblock-footer-menu idblock-footer> h2 classvisually-hidden idblock-footer-menu>Footer/h2> ul> li> a href/global/what-is-hyperkalaemia data-drupal-link-system-pathnode/351>What is Hyperkalaemia?/a> ul> li> a href/global/what-is-hyperkalaemia?sectionhomeostasis data-drupal-link-query{"section":"homeostasis"} data-drupal-link-system-pathnode/351>K+ Homeostasis is critical/a> /li> li> a href/global/what-is-hyperkalaemia?sectioncauses data-drupal-link-query{"section":"causes"} data-drupal-link-system-pathnode/351>What causes hyperkalaemia? /a> /li> li> a href/global/what-is-hyperkalaemia?sectioncondition data-drupal-link-query{"section":"condition"} data-drupal-link-system-pathnode/351>HK is a serious medical condition/a> /li> li> a href/global/what-is-hyperkalaemia?sectionrisk data-drupal-link-query{"section":"risk"} data-drupal-link-system-pathnode/351>CKD and HF patients are at Risk of HK/a> /li> /ul> /li> li> a href/global/hk-challenge-in-ckd data-drupal-link-system-pathnode/331>HK Challenge in CKD/a> ul> li> a href/global/hk-challenge-in-ckd?sectionckd-therapy data-drupal-link-query{"section":"ckd-therapy"} data-drupal-link-system-pathnode/331>RAASI therapy is vital/a> /li> li> a href/global/hk-challenge-in-ckd?sectionckd-exacerbated data-drupal-link-query{"section":"ckd-exacerbated"} data-drupal-link-system-pathnode/331>HK Risk is exacerbated by RAASI/a> /li> li> a href/global/hk-challenge-in-ckd?sectionckd-suboptimal data-drupal-link-query{"section":"ckd-suboptimal"} data-drupal-link-system-pathnode/331>HK leads to suboptimal RAASI use/a> /li> li> a href/global/hk-challenge-in-ckd?sectionckd-treatment-option data-drupal-link-query{"section":"ckd-treatment-option"} data-drupal-link-system-pathnode/331>Current treatment options are limited/a> /li> /ul> /li> li> a href/global/hk-challenge-in-hf data-drupal-link-system-pathnode/336>HK Challenge in HF/a> ul> li> a href/global/hk-challenge-in-hf?sectionhf-therapy data-drupal-link-query{"section":"hf-therapy"} data-drupal-link-system-pathnode/336>RAASI therapy is vital/a> /li> li> a href/global/hk-challenge-in-hf?sectionhf-risk data-drupal-link-query{"section":"hf-risk"} data-drupal-link-system-pathnode/336>HK Risk is exacerbated by RAASI/a> /li> li> a href/global/hk-challenge-in-hf?sectionhf-suboptimal data-drupal-link-query{"section":"hf-suboptimal"} data-drupal-link-system-pathnode/336>HK leads to suboptimal RAASI use/a> /li> li> a href/global/hk-challenge-in-hf?sectionhf-treatment data-drupal-link-query{"section":"hf-treatment"} data-drupal-link-system-pathnode/336>Current treatment options are limited/a> /li> /ul> /li> li> a href/global/about classlittle-sup data-drupal-link-system-pathnode/291>About Veltassa/a> ul> li> a href/global/about?sectionabout-what-is classlittle-sup-question data-drupal-link-query{"section":"about-what-is"} data-drupal-link-system-pathnode/291>What is Veltassa/a> /li> li> a href/global/about?sectionabout-mechanism classlittle-sup data-drupal-link-query{"section":"about-mechanism"} data-drupal-link-system-pathnode/291>Mechanism of action of Veltassa/a> /li> li> a href/global/about?sectionabout-use data-drupal-link-query{"section":"about-use"} data-drupal-link-system-pathnode/291>Easy to use/a> /li> /ul> /li> li> a href/global/clinical-experience data-drupal-link-system-pathnode/296>Clinical Experience/a> ul> li> a href/global/clinical-experience?sectionexperience-reliable data-drupal-link-query{"section":"experience-reliable"} data-drupal-link-system-pathnode/296>Reliable K+ Control /a> /li> li> a href/global/clinical-experience?sectionexperience-proven data-drupal-link-query{"section":"experience-proven"} data-drupal-link-system-pathnode/296>RAASI enablement/a> /li> li> a href/global/clinical-experience?sectionexperience-safety data-drupal-link-query{"section":"experience-safety"} data-drupal-link-system-pathnode/296>Favourable safety and tolerability/a> /li> li> a href/global/clinical-experience?sectionexperience-programme data-drupal-link-query{"section":"experience-programme"} data-drupal-link-system-pathnode/296>Clinical programme/a> /li> /ul> /li> li> a href/global/resources data-drupal-link-system-pathnode/346>Resources/a> ul> li> a href/global/resources?sectionresources-for-you data-drupal-link-query{"section":"resources-for-you"} data-drupal-link-system-pathnode/346>For you/a> /li> li> a href/global/resources?sectionresources-for-patients data-drupal-link-query{"section":"resources-for-patients"} data-drupal-link-system-pathnode/346>For your patients/a> /li> /ul> /li> /ul> /nav>div classfooter-text> div classdisclaimer> p>The information and materials for Veltassa contained in this website were prepared based on the EU SmPC. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC)./p>/div> div classtext> div classinner-container>p>Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd, a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care; Relypsa; and 0M Pharma. For more information about Vifor Pharma, please visit a hrefhttps://www.viforpharma.com/>www.viforpharma.com/a>/p>p>This site does not provide medical advice and may not be relied upon by any healthcare practitioner in exercising his or her professional judgement in the practice of medicine. The information provided herein is provided for general educational purposes only, and is not to be used or relied on for any diagnostic or treatment purposes. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed; rather the material is intended to present an approach, view, statement or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. VFMCRP makes no warranties or representations as to the site’s accuracy, completeness or up-to-date information. All users agree that access to this site is at their own risk, and that neither VFMCRP any party involved in creating or delivering this site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if VFMCRP has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this site. This limitation includes damages to, or for any viruses that may infect your computer equipment.br>© 2019 Vifor Fresenius Medical Care Renal Pharma/p>/div>/div> div classbottom-links> div classcontainer> div classlinks> a href/global/terms target_blank>Terms of use/a> a hrefhttps://privacy.csl.com/ target_blank>Privacy policy/a> a href/global/cookie-settings target_blank>Cookie policy/a> a hrefhttps://www.ema.europa.eu/en/medicines/human/EPAR/veltassa target_blank>Prescribing information/a> span classot-sdk-show-settings>COOKIE SETTINGS/span> /div> div classdate> HQ-PAT-2000046 | Date of preparation: December 2020/div> /div> /div>/div> /div> /div> script typeapplication/json data-drupal-selectordrupal-settings-json>{path:{baseUrl:\/,pathPrefix:,currentPath:node\/341,currentPathIsAdmin:false,isFront:true,currentLanguage:en},pluralDelimiter:\u0003,suppressDeprecationErrors:true,ajaxTrustedUrl:{\/search:true},user:{uid:0,permissionsHash:a0c2ac8405ada1d374bc24ef406722bdf880de0d9f38fc029f1698a4e5ed5f14}}/script>script srchttps://code.jquery.com/jquery-3.6.4.min.js>/script>script src/sites/multisite/veltassa/files/js/js_GJDDcyAMQQrNpqAB-EFr_Krt6Z9inqK6HuBGDl30ndo.js?scopefooter&delta1&languageen&themeveltassa_global&includeeJzLKixNLaqMT8kvz0svSkxJ1c-CCOSkpicmV-qUpeaUJBYXJ8an5-QnJeboQyjdrGIAi0wWZw>/script>script src/themes/custom/veltassa_global/js/lib/custom.js?v1&t9989k defer>/script>script src/sites/multisite/veltassa/files/js/js_zmIjmy5tLxq16RyXZ_b4jUdkE6ndkdU8XulXTcmgqRs.js?scopefooter&delta3&languageen&themeveltassa_global&includeeJzLKixNLaqMT8kvz0svSkxJ1c-CCOSkpicmV-qUpeaUJBYXJ8an5-QnJeboQyjdrGIAi0wWZw>/script>/js-bottom-placeholder> /body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]